Our in vivo experiments revealed a greater increase in TNF mRNA abundance (>1000-fold increase) in TP53-GOF mutant cells treated with osimertinib compared with that observed in our in vitro experiments (~200-fold increase), suggesting that the tumor microenvironment including macrophages and fibroblasts might contribute to this in vivo effect. This evidence concerns the gene TNF and neoplasm.